March 11, 2013
Authored and Edited by Denise W. DeFranco
What is a transition application? A “transition application” is any nonprovisional application that is filed on or after March 16, 2013, that claims the benefit of the filing date of a pre-AIA (filed prior to March 16, 2013) provisional, foreign, nonprovisional, or PCT application that designates the United States. An application is considered a transition application if it meets these filing requirements regardless of whether or not it adds or claims new matter.
Where a transition application adds new matter and that new matter is claimed (or ever was claimed) in the transition application, the applicant must provide a statement to the U.S. Patent and Trademark Office (USPTO) indicating that the transition application contains at least one claim supported by the added matter. In other words, the statement is an affirmation that the transition application has at least one claim having an AIA effective filing date. If the transition application discloses but does not claim new matter, no statement is needed.
Why does the USPTO require a statement? The submission of a statement in a transition application assists the USPTO by alerting them that the transition application should be examined under AIA. Where no statement is provided, the USPTO will presume that the transition application does not claim new matter and will examine the applications under pre-AIA law.
When must a statement be made? If a statement is required, it must be submitted no later than 4 months from the actual filing date of the transition application, 16 months from the filing date of the priority application, or on the date when the first claim with an AIA effective filing date is presented.
According to the USPTO, if the applicant “reasonably believes on the basis of information already known” that the transition application does not, and did not at any time, claim new matter, no statement is required. See, e.g., Changes To Implement the First Inventor to File Provisions of the Leahy-Smith America Invents Act, 78 Fed. Reg. 31, 11027 (Feb. 14, 2013) (to be codified at 37 C.F.R. pt. 1)
Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.